Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation
Background Pre-procedural and post-procedural plasma B-type natriuretic peptide (BNP) levels can predict rhythm outcomes after catheter ablation for atrial fibrillation (AF). However, the significance of long-term events remains unclear. Therefore, this study aimed to investigate the significance of...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-02-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/12/1/e003251.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043659376918528 |
|---|---|
| author | Shigeki Kobayashi Shohei Fujii Hironori Ishiguchi Masakazu Fukuda Yasuhiro Yoshiga Masahiro Hisaoka Shintaro Hashimoto Takuya Omuro Noriko Fukue Motoaki Sano |
| author_facet | Shigeki Kobayashi Shohei Fujii Hironori Ishiguchi Masakazu Fukuda Yasuhiro Yoshiga Masahiro Hisaoka Shintaro Hashimoto Takuya Omuro Noriko Fukue Motoaki Sano |
| author_sort | Shigeki Kobayashi |
| collection | DOAJ |
| description | Background Pre-procedural and post-procedural plasma B-type natriuretic peptide (BNP) levels can predict rhythm outcomes after catheter ablation for atrial fibrillation (AF). However, the significance of long-term events remains unclear. Therefore, this study aimed to investigate the significance of integrating pre-ablation and post-ablation BNP levels on major adverse cardiovascular events (MACE) and arrhythmic recurrence in patients with persistent AF undergoing catheter ablation.Methods We analysed 392 patients who underwent first catheter ablation. Patients were stratified into four subgroups based on pre-ablation plasma BNP level and its relative change after ablation (ΔBNP) using their respective median values (pre-ablation BNP: 148.0 pg/mL, ΔBNP: −52.6%): Low-Low (pre-ablation<148.0 pg/mL, ΔBNP<−52.6%), Low-High (pre-ablation<148.0 pg/mL, ΔBNP≥−52.6%), High-Low (pre-ablation≥148.0 pg/mL, ΔBNP<−52.6%) and High-High (pre-ablation≥148.0 pg/mL, ΔBNP≥−52.6%). The primary endpoint was MACE, which included all-cause death, heart failure hospitalisation and other cardiovascular hospitalisations. The secondary endpoint involved arrhythmic recurrence.Results Of the 392 patients, 101 were classified as Low-Low, 91 as Low-High, 97 as High-Low and 103 as High-High. During a median follow-up of 5.3 (IQR: 3.2–7.2) years, 63 patients (16%) experienced MACE. Heart failure hospitalisation accounted for the majority of events (63%). The High-High subgroup showed significantly higher MACE rates than others (cumulative incidence (95% CI): 26.3% (16.2% to 35.2%), p<0.001). Low-High and High-High subgroups demonstrated a higher arrhythmic recurrence (p<0.001). After multivariate adjustment, the High-Low and High-High subgroups demonstrated progressively higher risks of MACE incidence compared with the Low-Low and Low-High subgroups. Both Low-High and High-High subgroups showed an elevated arrhythmic recurrence risk (both p<0.001).Conclusions Integrating pre-ablation and post-ablation BNP levels can be useful for identifying patients with persistent AF at high risk of MACE and arrhythmic recurrence during long-term follow-up. |
| format | Article |
| id | doaj-art-cf0f5e7a0b604a61bdfca3123d4b32ac |
| institution | DOAJ |
| issn | 2053-3624 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Open Heart |
| spelling | doaj-art-cf0f5e7a0b604a61bdfca3123d4b32ac2025-08-20T02:55:10ZengBMJ Publishing GroupOpen Heart2053-36242025-02-0112110.1136/openhrt-2025-003251Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillationShigeki Kobayashi0Shohei Fujii1Hironori Ishiguchi2Masakazu Fukuda3Yasuhiro Yoshiga4Masahiro Hisaoka5Shintaro Hashimoto6Takuya Omuro7Noriko Fukue8Motoaki Sano9Department of Therapeutic Science for Heart Failure in the Elderly, Yamaguchi University School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanDepartment of Medicine and Clinical Science, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Ube, JapanYamaguchi University Wellness Science Center, Yamaguchi, JapanDivision of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, JapanBackground Pre-procedural and post-procedural plasma B-type natriuretic peptide (BNP) levels can predict rhythm outcomes after catheter ablation for atrial fibrillation (AF). However, the significance of long-term events remains unclear. Therefore, this study aimed to investigate the significance of integrating pre-ablation and post-ablation BNP levels on major adverse cardiovascular events (MACE) and arrhythmic recurrence in patients with persistent AF undergoing catheter ablation.Methods We analysed 392 patients who underwent first catheter ablation. Patients were stratified into four subgroups based on pre-ablation plasma BNP level and its relative change after ablation (ΔBNP) using their respective median values (pre-ablation BNP: 148.0 pg/mL, ΔBNP: −52.6%): Low-Low (pre-ablation<148.0 pg/mL, ΔBNP<−52.6%), Low-High (pre-ablation<148.0 pg/mL, ΔBNP≥−52.6%), High-Low (pre-ablation≥148.0 pg/mL, ΔBNP<−52.6%) and High-High (pre-ablation≥148.0 pg/mL, ΔBNP≥−52.6%). The primary endpoint was MACE, which included all-cause death, heart failure hospitalisation and other cardiovascular hospitalisations. The secondary endpoint involved arrhythmic recurrence.Results Of the 392 patients, 101 were classified as Low-Low, 91 as Low-High, 97 as High-Low and 103 as High-High. During a median follow-up of 5.3 (IQR: 3.2–7.2) years, 63 patients (16%) experienced MACE. Heart failure hospitalisation accounted for the majority of events (63%). The High-High subgroup showed significantly higher MACE rates than others (cumulative incidence (95% CI): 26.3% (16.2% to 35.2%), p<0.001). Low-High and High-High subgroups demonstrated a higher arrhythmic recurrence (p<0.001). After multivariate adjustment, the High-Low and High-High subgroups demonstrated progressively higher risks of MACE incidence compared with the Low-Low and Low-High subgroups. Both Low-High and High-High subgroups showed an elevated arrhythmic recurrence risk (both p<0.001).Conclusions Integrating pre-ablation and post-ablation BNP levels can be useful for identifying patients with persistent AF at high risk of MACE and arrhythmic recurrence during long-term follow-up.https://openheart.bmj.com/content/12/1/e003251.full |
| spellingShingle | Shigeki Kobayashi Shohei Fujii Hironori Ishiguchi Masakazu Fukuda Yasuhiro Yoshiga Masahiro Hisaoka Shintaro Hashimoto Takuya Omuro Noriko Fukue Motoaki Sano Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation Open Heart |
| title | Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| title_full | Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| title_fullStr | Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| title_full_unstemmed | Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| title_short | Integrating pre-ablation and post-ablation B-type natriuretic peptide to identify high-risk population for long-term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| title_sort | integrating pre ablation and post ablation b type natriuretic peptide to identify high risk population for long term adverse events and arrhythmic recurrence in persistent atrial fibrillation |
| url | https://openheart.bmj.com/content/12/1/e003251.full |
| work_keys_str_mv | AT shigekikobayashi integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT shoheifujii integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT hironoriishiguchi integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT masakazufukuda integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT yasuhiroyoshiga integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT masahirohisaoka integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT shintarohashimoto integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT takuyaomuro integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT norikofukue integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation AT motoakisano integratingpreablationandpostablationbtypenatriureticpeptidetoidentifyhighriskpopulationforlongtermadverseeventsandarrhythmicrecurrenceinpersistentatrialfibrillation |